Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BerGenBio ASA ( (BRRGF) ) has issued an announcement.
BerGenBio ASA and Oncoinvent ASA have announced the completion of their merger through a statutory triangular merger, with the final trading day for Oncoinvent shares on Euronext Growth Oslo being 29 October 2025. This merger is expected to enhance the combined company’s market position and operational capabilities, potentially benefiting stakeholders by expanding their reach in the biotechnology sector.
The most recent analyst rating on (BRRGF) stock is a Buy with a NOK38.00 price target. To see the full list of analyst forecasts on BerGenBio ASA stock, see the BRRGF Stock Forecast page.
More about BerGenBio ASA
Oncoinvent is a clinical-stage biotechnology company focused on developing innovative radiopharmaceutical therapies for cancer treatment. Their lead product, Radspherin®, utilizes radium-224 to target micro-metastases post-surgery, and is currently undergoing clinical trials in the US, UK, and Europe.
Average Trading Volume: 82,805
Current Market Cap: NOK45.18M
For detailed information about BRRGF stock, go to TipRanks’ Stock Analysis page.